Shenyang Xingqi Pharmaceutical (300573) Fundamentals 2026 — P/E 13.1x, Revenue Analysis | SniperIQ
Shenyang Xingqi Pharmaceutical (300573) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥14.4B, trading at ¥40.42 on the SHZ. This SniperIQ fundamentals page covers Shenyang Xingqi Pharmaceutical's valuation (P/E 13.1x, P/B 4.5x), profitability (net margin 28.9%), revenue (¥2.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shenyang Xingqi Pharmaceutical's market cap?
Shenyang Xingqi Pharmaceutical (300573) has a market capitalization of approximately ¥14.4B, trading at ¥40.42 on the SHZ. Market cap moves with the live share price.
What is Shenyang Xingqi Pharmaceutical's P/E ratio?
Shenyang Xingqi Pharmaceutical's trailing twelve-month P/E ratio is 13.1x, with a price-to-book (P/B) of 4.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shenyang Xingqi Pharmaceutical?
Shenyang Xingqi Pharmaceutical runs a net profit margin of 28.9%, a gross margin of 81.3%, and an operating margin of 33.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shenyang Xingqi Pharmaceutical generate?
Shenyang Xingqi Pharmaceutical reported revenue of ¥2.5B for fiscal year 2025, with net income of ¥696M and earnings per share (EPS) of 2.83. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shenyang Xingqi Pharmaceutical pay a dividend?
Shenyang Xingqi Pharmaceutical offers a trailing dividend yield of about 3.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shenyang Xingqi Pharmaceutical financially healthy?
Shenyang Xingqi Pharmaceutical carries a debt-to-equity ratio of 0.04x and a current ratio of 2.23x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shenyang Xingqi Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shenyang Xingqi Pharmaceutical (300573) the key facts are: market cap ¥14.4B, P/E 13.1x, revenue ¥2.5B, 52-week range 35.1-59.06897. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shenyang Xingqi Pharmaceutical's full fundamentals live
Get Shenyang Xingqi Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.